CN116732012A - Base editor and application thereof - Google Patents
Base editor and application thereof Download PDFInfo
- Publication number
- CN116732012A CN116732012A CN202310517357.6A CN202310517357A CN116732012A CN 116732012 A CN116732012 A CN 116732012A CN 202310517357 A CN202310517357 A CN 202310517357A CN 116732012 A CN116732012 A CN 116732012A
- Authority
- CN
- China
- Prior art keywords
- protein
- fusion protein
- adenosine deaminase
- cas
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 92
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 82
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 82
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims abstract description 69
- 102000055025 Adenosine deaminases Human genes 0.000 claims abstract description 69
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 59
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 59
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims abstract description 31
- 101710096438 DNA-binding protein Proteins 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 120
- 102000004169 proteins and genes Human genes 0.000 claims description 91
- 235000018102 proteins Nutrition 0.000 claims description 89
- 239000013598 vector Substances 0.000 claims description 61
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 37
- 108020005004 Guide RNA Proteins 0.000 claims description 33
- 102000040430 polynucleotide Human genes 0.000 claims description 32
- 108091033319 polynucleotide Proteins 0.000 claims description 32
- 239000002157 polynucleotide Substances 0.000 claims description 32
- 230000035772 mutation Effects 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 238000010362 genome editing Methods 0.000 claims description 22
- 238000006467 substitution reaction Methods 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 108091033409 CRISPR Proteins 0.000 claims description 8
- 230000030648 nucleus localization Effects 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 235000004252 protein component Nutrition 0.000 claims description 3
- 108010088141 Argonaute Proteins Proteins 0.000 claims description 2
- 102000008682 Argonaute Proteins Human genes 0.000 claims description 2
- 101150069031 CSN2 gene Proteins 0.000 claims description 2
- 101100275895 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) csnB gene Proteins 0.000 claims description 2
- 230000037429 base substitution Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 108010021466 Mutant Proteins Proteins 0.000 abstract description 2
- 102000008300 Mutant Proteins Human genes 0.000 abstract description 2
- 101710163270 Nuclease Proteins 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 72
- 235000001014 amino acid Nutrition 0.000 description 44
- 229940024606 amino acid Drugs 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 23
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 21
- 125000000539 amino acid group Chemical group 0.000 description 21
- 230000008685 targeting Effects 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 241000196324 Embryophyta Species 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 12
- 210000003527 eukaryotic cell Anatomy 0.000 description 12
- 238000001890 transfection Methods 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 9
- 244000241257 Cucumis melo Species 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 210000001236 prokaryotic cell Anatomy 0.000 description 7
- 238000010453 CRISPR/Cas method Methods 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 102220520951 N-chimaerin_I95M_mutation Human genes 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- 210000004102 animal cell Anatomy 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 244000291564 Allium cepa Species 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 102220520956 N-chimaerin_I95V_mutation Human genes 0.000 description 4
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 235000009973 maize Nutrition 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 230000003007 single stranded DNA break Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 240000007124 Brassica oleracea Species 0.000 description 3
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 3
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 3
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 3
- 244000221633 Brassica rapa subsp chinensis Species 0.000 description 3
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 3
- 235000007542 Cichorium intybus Nutrition 0.000 description 3
- 244000298479 Cichorium intybus Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 3
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 235000002597 Solanum melongena Nutrition 0.000 description 3
- 244000061458 Solanum melongena Species 0.000 description 3
- 240000003829 Sorghum propinquum Species 0.000 description 3
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 244000098338 Triticum aestivum Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- -1 grnas Proteins 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 241000209763 Avena sativa Species 0.000 description 2
- 235000007558 Avena sp Nutrition 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- 244000304217 Brassica oleracea var. gongylodes Species 0.000 description 2
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 240000007154 Coffea arabica Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 244000019459 Cynara cardunculus Species 0.000 description 2
- 235000019106 Cynara scolymus Nutrition 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 241000219146 Gossypium Species 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 235000003228 Lactuca sativa Nutrition 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000016520 artichoke thistle Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 235000016213 coffee Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 235000021384 green leafy vegetables Nutrition 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 102220034830 rs62508682 Human genes 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000000277 virosome Substances 0.000 description 2
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010052875 Adenine deaminase Proteins 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 1
- 101100385358 Alicyclobacillus acidoterrestris (strain ATCC 49025 / DSM 3922 / CIP 106132 / NCIMB 13137 / GD3B) cas12b gene Proteins 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000010167 Allium cepa var aggregatum Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000093727 Berzelia alopecuroides Species 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241000237519 Bivalvia Species 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 235000001171 Brassica oleracea var gongylodes Nutrition 0.000 description 1
- 240000008100 Brassica rapa Species 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 101100011365 Caenorhabditis elegans egl-13 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000009025 Carya illinoensis Nutrition 0.000 description 1
- 244000068645 Carya illinoensis Species 0.000 description 1
- 108700004991 Cas12a Proteins 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 241000010804 Caulobacter vibrioides Species 0.000 description 1
- 235000003301 Ceiba pentandra Nutrition 0.000 description 1
- 244000146553 Ceiba pentandra Species 0.000 description 1
- 235000010523 Cicer arietinum Nutrition 0.000 description 1
- 244000045195 Cicer arietinum Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 240000000491 Corchorus aestuans Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- 241000723382 Corylus Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 102000017013 Heterogeneous Nuclear Ribonucleoprotein A1 Human genes 0.000 description 1
- 108010014594 Heterogeneous Nuclear Ribonucleoprotein A1 Proteins 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 235000010702 Insulata Nutrition 0.000 description 1
- 244000165077 Insulata Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 235000015802 Lactuca sativa var crispa Nutrition 0.000 description 1
- 240000004201 Lactuca sativa var. crispa Species 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 240000004322 Lens culinaris Species 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000307609 Mangifera caesia Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000010804 Maranta arundinacea Nutrition 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000004370 Pastinaca sativa Species 0.000 description 1
- 235000017769 Pastinaca sativa subsp sativa Nutrition 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 240000003889 Piper guineense Species 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 240000006711 Pistacia vera Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 244000141353 Prunus domestica Species 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006029 Prunus persica var nucipersica Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000017714 Prunus persica var. nucipersica Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 235000011552 Rhamnus crocea Nutrition 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 241000863432 Shewanella putrefaciens Species 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 244000145580 Thalia geniculata Species 0.000 description 1
- 235000012419 Thalia geniculata Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 241000482268 Zea mays subsp. mays Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 235000020639 clam Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000002003 electron diffraction Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 244000037666 field crops Species 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000020233 pistachio Nutrition 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 235000021013 raspberries Nutrition 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 102220035366 rs281865432 Human genes 0.000 description 1
- 102220043361 rs73866065 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 101150059931 tus gene Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04004—Adenosine deaminase (3.5.4.4)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the field of nucleic acid editing, in particular to the technical field of regularly clustered interval short palindromic repeat (CRISPR). In particular, the invention provides a fusion protein comprising a DNA-binding protein and a deaminase, wherein the DNA-binding protein in the fusion protein is a Cas mutant protein with inactive nuclease activity. The invention fuses the adenosine deaminase with DNA binding protein by improving the adenosine deaminase, can be used for single base editing of target nucleic acid, and has wide application prospect.
Description
Technical Field
The invention relates to the field of gene editing, in particular to the technical field of regular clustered interval short palindromic repeat (CRISPR). In particular, the invention relates to a base editing tool, in particular to a base editing tool based on a mutated adenosine deaminase.
Background
CRISPR/Cas technology is a widely used gene editing technology that uses RNA-guided specific binding of target sequences on the genome and cleavage of DNA to create double strand breaks, site-directed gene editing using biological non-homologous end joining or homologous recombination.
The development of single base gene editing tools can realize the accurate modification of specific gene loci without causing DNA double strand breaks. The conversion of A > G (from A to G) is achieved based on the Adenine Base Editor (ABE) of adenosine deaminase. At present, the application of an adenine base editor is limited by the limited compatibility of an adenosine deaminase structural domain and a DNA binding protein, so that the invention constructs a single base editing tool based on a mutant adenosine deaminase, expands the application range of a single base editing technology, and improves the single base editing efficiency.
Disclosure of Invention
In one aspect, the invention provides a mutant adenosine deaminase.
In one embodiment, the adenosine deaminase has a mutation at the 95 th amino acid position corresponding to the amino acid sequence shown in SEQ ID No.1, compared to the amino acid sequence of the parent adenosine deaminase.
In one embodiment, the amino acid at position 95 is mutated to a non-I amino acid, e.g., a, V, G, L, Q, F, W, Y, D, N, E, K, M, T, C, P, H, R, S; preferably A, N, F or R.
In one embodiment, the amino acid sequence of the parent adenosine deaminase has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity as compared to SEQ ID No. 1.
MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYSTFEPCVMCAGAMIHSRIGRVVFGVRNSKRGAAGSLMNVLNYPGMNHRVEITEGILADECAALLCDFYRMPRRVFNAQKKAQSSIN(SEQ ID No.1)
In one embodiment, the amino acid sequence of the parent adenosine deaminase is shown as SEQ ID No. 1.
In the present invention, an adenosine deaminase, also known as adenine deaminase, catalyzes the hydrolytic deamination of adenine or adenosine. The adenosine deaminase provided herein (e.g., engineered adenosine deaminase, evolved adenosine deaminase) can be from any organism, such as a bacterium.
In some embodiments, the adenosine deaminase is a naturally occurring adenosine deaminase, as well as a variant that is mutated but still has adenosine deaminase activity.
In some embodiments, the adenosine deaminase is from a prokaryote. In some embodiments, the adenosine deaminase is from a bacterium. In some embodiments, the adenosine deaminase is derived from Escherichia coli (Escherichia coli), staphylococcus aureus (Staphylococcus aureus), salmonella typhimurium (Salmonella typhi), shiva putrefying (Shewanella putrefaciens), haemophilus influenzae (Haemophilus influenzae), candida crescens (Caulobacter crescentus), or bacillus subtilis (Bacillus subtilis).
In some embodiments, the adenosine deaminase is TadA deaminase. In some embodiments, the TadA deaminase is an escherichia coli TadA deaminase, but also a variant of a TadA deaminase, e.g., tadA7-10, e.g., tadA9.
In some embodiments, the TadA deaminase is an escherichia coli TadA deaminase (ecTadA). In some embodiments, the TadA deaminase is a truncated e.coli TadA deaminase. For example, a truncated ecTadA may have one or more N-terminal amino acids deleted relative to the full length ecTadA. In some embodiments, a truncated ecTadA can have a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20N-terminal amino acid residues relative to a full length ecTadA. In some embodiments, a truncated ecTadA can have a deletion of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20C-terminal amino acid residues relative to a full length ecTadA. In some embodiments, the ecTadA deaminase does not comprise an N-terminal methionine.
In a preferred embodiment, the parent adenosine deaminase of the present invention is derived from E.coli.
In one aspect, the invention provides a fusion protein comprising a DNA binding protein and an adenosine deaminase as described above.
In one embodiment, the DNA-binding protein is a nucleic acid programmable DNA-binding protein (napDNAbp) domain, and the "DNA-binding protein" or "DNA-binding protein domain" refers to any protein that is capable of localizing and binding to a particular target DNA nucleotide sequence (e.g., a genomic locus). In one embodiment, the DNA-binding protein is a Cas protein selected from Cas9, cas9n, dCas9, casX, casY, C cl, C2, C2C3, geoCas9, cjCas9, casl2a, casl2b, casl2g, casl2h, casl2i, cas12j, casl3b, casl3C, casl3d, casl4, csn2, xCas9, cas9-NG, lbCasl2a, enaascas 2a, cas9-KKH, cyclic substitution Cas9, argonaute (Ago) domains, smacas 9, spy-macCas9, spGas9-NRRH, spaCas9-NRTH, spa 9-NRCH, cas 9-CP 1041, cas 9-NG-vrs 12i, cas12i, and Cas12i and variants thereof.
In one embodiment, the Cas protein is Cas12i.
In one embodiment, the Cas protein may be naturally occurring or may be non-naturally occurring engineered.
In one embodiment, the Cas protein is a nuclease-inactivated Cas protein (dCas).
In one embodiment, the amino acid sequence of the Cas protein is shown in SEQ ID No.2 (dCas 12i 3).
In one embodiment, the amino acid sequence of the Cas protein is mutated at amino acid positions 235 and 328 of SEQ ID No.2 relative to the amino acid sequence shown in SEQ ID No. 2. That is, the Cas protein is a Cas protein obtained by mutating a protein shown in SEQ ID No.2 at amino acid positions 235 and 328 thereof.
In one embodiment, the amino acid at position 235 is mutated to an amino acid other than T, e.g., a, V, G, L, Q, F, W, Y, D, N, E, K, M, S, C, P, H, R, I; preferably, R.
In one embodiment, the amino acid at position 328 is simultaneously mutated to a non-E amino acid, e.g., a, V, G, L, Q, F, W, Y, D, N, T, K, M, S, C, P, H, R, I, based on the mutation at the amino acid position 235; preferably, R.
In one embodiment, the DNA-binding protein in the fusion protein is fused N-terminal to an adenosine deaminase, and in other embodiments, the DNA-binding protein in the fusion protein is fused C-terminal to a deaminase.
In one embodiment, the DNA binding protein and the adenosine deaminase in the fusion protein are linked by a linker.
In the present invention, linkers may be used to attach any peptide or protein domain of the present invention. In certain embodiments, the linker is a polypeptide. In certain embodiments, the linker is a covalent bond (e.g., a carbon-carbon bond, disulfide bond, carbon-heteroatom bond, etc.). In certain embodiments, the linker is an amide-linked carbon-nitrogen bond. In certain embodiments, the linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic or heteroaliphatic linker. In certain embodiments, the linker is polymeric (e.g., polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of an aminoalkanoic acid. In certain embodiments, the linker comprises an aminoalkanoic acid (e.g., glycine, acetic acid, alanine, beta-alanine, 3-aminopropionic acid, 4-aminobutyric acid, 5-pentanoic acid, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminocaproic acid (Ahx). In certain embodiments, the linker is based on a carbocyclic moiety (e.g., cyclopentane, cyclohexane). In other embodiments, the linker comprises a polyethylene glycol moiety (PEG). In other embodiments, the linker comprises an amino acid. In certain embodiments, the linker comprises a peptide. In certain embodiments, the linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a benzene ring. The linker may comprise a functionalized moiety to facilitate attachment of nucleophiles (e.g., thiols, amino groups) from the peptide to the linker. Any electrophile may be used as part of the linker.
In one embodiment, the linker is an XTEN linker, preferably having the amino acid sequence shown in SEQ id No. 3.
SGGSSGGSSGSETPGTSESATPESSGGSSGGS(SEQ ID No.3)。
In one embodiment, the fusion protein of the invention further comprises a Nuclear Localization Sequence (NLS). In some embodiments, the NLS is fused to the N-terminus of the fusion protein. In some embodiments, the NLS is fused to the C-terminus of the fusion protein. In other embodiments, both the N-and C-segments of the fusion protein are linked to NLS.
In some embodiments, the NLS is fused to the N-terminus of the Cas protein. In some embodiments, the NLS is fused to the C-terminus of the Cas protein. In some embodiments, the NLS is fused to the N-terminus of the deaminase. In some embodiments, the NLS is fused to the C-terminus of the deaminase. In some embodiments, the NLS is fused to the fusion protein via one or more linkers. In some embodiments, the NLS is fused to the fusion protein without a linker.
The Nuclear Localization Sequence (NLS) is known in the art and will be apparent to the skilled person, in some embodiments the sequence of the NLS comprises the amino acid sequence PKKKRKVM (SEQ ID No. 4), or KRPAATKKAGQAKKKK (SEQ ID No. 5).
It will be apparent to those skilled in the art that the structure of a protein may be altered without adversely affecting its activity and functionality, for example, one or more conservative amino acid substitutions may be introduced into the amino acid sequence of the protein without adversely affecting the activity and/or three-dimensional structure of the protein molecule. Examples and embodiments of conservative amino acid substitutions are apparent to those skilled in the art. In particular, the amino acid residue may be substituted with another amino acid residue belonging to the same group as the site to be substituted, i.e., with a nonpolar amino acid residue, with a polar uncharged amino acid residue, with a basic amino acid residue, with an acidic amino acid residue. Such substituted amino acid residues may or may not be encoded by the genetic code. Conservative substitutions of one amino acid by another belonging to the same group are within the scope of the invention as long as the substitution does not result in inactivation of the biological activity of the protein. Thus, the proteins of the invention may comprise one or more conservative substitutions in the amino acid sequence, which are preferably made according to table 1. In addition, proteins that also contain one or more other non-conservative substitutions are also contemplated by the present invention, provided that the non-conservative substitutions do not significantly affect the desired function and biological activity of the proteins of the present invention.
Conservative amino acid substitutions may be made at one or more predicted nonessential amino acid residues. "nonessential" amino acid residues are amino acid residues that can be altered (deleted, substituted or substituted) without altering the biological activity, whereas "essential" amino acid residues are required for the biological activity. A "conservative amino acid substitution" is a substitution in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Amino acid substitutions may be made in non-conserved regions of the Cas muteins or fusion proteins described above. In general, such substitutions are not made to conserved amino acid residues, or amino acid residues that are within a conserved motif, where such residues are required for protein activity. However, it will be appreciated by those skilled in the art that functional variants may have fewer conservative or non-conservative changes in the conserved regions.
TABLE 1
Initial residues | Representative substitution | Preferred substitution |
Ala(A) | Val;Leu;Ile | Val |
Arg(R) | Lys;Gln;Asn | Lys |
Asn(N) | Gln;His;Lys;Arg | Gln |
Asp(D) | Glu | Glu |
Cys(C) | Ser | Ser |
Gln(Q) | Asn | Asn |
Glu(E) | Asp | Asp |
Gly(G) | Pro;Ala | Ala |
His(H) | Asn;Gln;Lys;Arg | Arg |
Ile(I) | Leu;Val;Met;Ala;Phe | Leu |
Leu(L) | Ile;Val;Met;Ala;Phe | Ile |
Lys(K) | Arg;Gln;Asn | Arg |
Met(M) | Leu;Phe;Ile | Leu |
Phe(F) | Leu;Val;Ile;Ala;Tyr | Leu |
Pro(P) | Ala | Ala |
Ser(S) | Thr | Thr |
Thr(T) | Ser | Ser |
Trp(W) | Tyr;Phe | Tyr |
Tyr(Y) | Trp;Phe;Thr;Ser | Phe |
Val(V) | Ile;Leu;Met;Phe;Ala | Leu |
It is well known in the art that one or more amino acid residues may be altered (substituted, deleted, truncated or inserted) from the N-and/or C-terminus of a protein while still retaining its functional activity. Thus, proteins that have one or more amino acid residues altered from the N-and/or C-terminus of a Cas mutant protein while retaining their desired functional activity are also within the scope of the invention. These changes may include changes introduced by modern molecular methods such as PCR, including PCR amplification that alters or extends the protein coding sequence by including an amino acid coding sequence in the oligonucleotides used in the PCR amplification.
It will be appreciated that proteins may be altered in a variety of ways, including amino acid substitutions, deletions, truncations and insertions, and that methods for such manipulation are generally known in the art. For example, amino acid sequence variants of the above proteins can be prepared by mutation of DNA. Single or multiple amino acid substitutions, deletions and/or insertions may also be made by other forms of mutagenesis and/or by directed evolution, for example, using known mutagenesis, recombination and/or shuffling (shuffleling) methods, in combination with associated screening methods.
Those skilled in the art will appreciate that these minor amino acid changes in the Cas proteins of the invention may occur (e.g., naturally occurring mutations) or be generated (e.g., using r-DNA technology) without loss of protein function or activity. If these mutations occur in the catalytic domain, active site or other functional domain of the protein, the nature of the polypeptide may be altered, but the polypeptide may retain its activity. Smaller effects can be expected if mutations are present that are not close to the catalytic domain, active site or other functional domain.
The skilled artisan can identify the essential amino acids of the Cas muteins of the invention according to methods known in the art, such as site-directed mutagenesis or protein evolution or analysis of bioinformatics. The catalytic, active or other functional domains of a protein can also be determined by physical analysis of the structure, such as by the following techniques: such as nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, in combination with mutations in the amino acids at putative key sites.
In the present application, amino acid residues may be represented by single letters or by three letters, for example: alanine (Ala, A), valine (Val, V), glycine (Gly, G), leucine (Leu, L), glutamine (Gln, Q), phenylalanine (Phe, F), tryptophan (Trp, W), tyrosine (Tyr, Y), aspartic acid (Asp, D), asparagine (Asn, N), glutamic acid (Glu, E), lysine (Lys, K), methionine (Met, M), serine (Ser, S), threonine (Thr, T), cysteine (Cys, C), proline (Pro, P), isoleucine (Ile, I), histidine (His, H), arginine (Arg, R).
The term "AxxB" means that amino acid a in position xx is changed to amino acid B, e.g. I95R means that I in position 95 is mutated to R. When multiple amino acid sites are mutated simultaneously, it can be expressed in a form similar to T235R-E328R, for example, T235R-E328R represents a T mutation at position 235 to R while E at position 328 is mutated to R.
The specific amino acid positions (numbering) within the proteins of the application are determined by aligning the amino acid sequence of the protein of interest with the sequence of interest (e.g., SEQ ID No. 1) using standard sequence alignment tools, such as by aligning the two sequences using the Smith-Waterman algorithm or using the CLUSTALW2 algorithm, wherein the sequences are considered aligned when the alignment score is highest. The alignment score can be calculated as described in Wilbur, W.J. and Lipman, D.J. (1983) Rapid similarity searches ofnucleic acid and protein data banks, proc.Natl. Acad.Sci.USA, 80:726-730. Default parameters are preferably used in the ClustalW2 (1.82) algorithm: protein gap opening penalty = 10.0; protein gap extension penalty = 0.2; protein matrix = Gonnet; protein/DNA endplay= -1; protein/DNAGAPDIST =4. The position of a specific amino acid within a protein according to the application is preferably determined by aligning the amino acid sequence of the protein with SEQ ID No.1 using the AlignX program (part of the vectorNTI group) with default parameters (gap opening penalty: 10 g gap extension penalty 0.05) suitable for multiple alignments. The amino acid sequence of any parent Cas protein can be compared and aligned (aligned) with SEQ ID No.1 using software commonly used in the art, such as Clustal Omega, to obtain the amino acid position in the parent Cas protein corresponding to the amino acid position defined based on SEQ ID No.1 as described herein.
The fusion protein of the present invention is not limited to the manner of production, and for example, it can be produced by genetic engineering methods (recombinant techniques) or by chemical synthesis methods.
The invention also provides a base editing tool, e.g., a single base editing tool, comprising the fusion protein described above.
Nucleic acid
In another aspect, the invention provides an isolated polynucleotide comprising:
(a) Polynucleotide sequences encoding mutant adenosine deaminase or fusion proteins of the present invention;
alternatively, a polynucleotide complementary to the polynucleotide of (a).
In one embodiment, the nucleotide sequence is codon optimized for expression in a prokaryotic cell. In one embodiment, the nucleotide sequence is codon optimized for expression in eukaryotic cells.
In one embodiment, the cell is an animal cell, e.g., a mammalian cell.
In one embodiment, the cell is a human cell.
In one embodiment, the cell is a plant cell, such as a cell of a cultivated plant (e.g., cassava, maize, sorghum, wheat, or rice), algae, tree, or vegetable.
In one embodiment, the polynucleotide is preferably single-stranded or double-stranded.
Guide RNA (gRNA)
In another aspect, the invention provides a gRNA that includes a protein binding sequence and a targeting sequence that targets a target nucleic acid.
The protein binding sequence of the gRNA is capable of interacting with the DNA binding protein (Cas protein) in the fusion protein of the invention, thereby forming a complex of the DNA binding protein (Cas protein) and the gRNA.
Designing grnas that interact with Cas proteins of the invention is a matter of routine skill in the art. For example, designing a gRNA that interacts with Cas9 proteins, cas proteins of the Cas12 family (including but not limited to Cas12a, cas12b, cas12i, etc.) does not require inventive effort.
The targeting sequence of the targeting nucleic acid of the invention comprises a nucleotide sequence complementary to a sequence in the target nucleic acid. In other words, the targeting sequence of the targeting nucleic acid or targeting segment of the targeting nucleic acid of the invention interacts with the target nucleic acid in a sequence-specific manner via hybridization (i.e., base pairing). Thus, the targeting sequence of the targeting nucleic acid or targeting segment of the targeting nucleic acid may be altered, or may be modified to hybridize to any desired sequence within the target nucleic acid. The nucleic acid is selected from DNA or RNA.
The targeting sequence of the targeting nucleic acid or the percentage of complementarity between the targeting segment of the targeting nucleic acid and the target sequence of the target nucleic acid can be at least 60% (e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%).
The "protein binding sequences" of the grnas of the invention can interact with a CRISPR protein (or Cas protein). The gRNA of the invention directs its interacting DNA-binding proteins to specific nucleotide sequences within the target nucleic acid by the action of the targeting sequence of the targeting nucleic acid.
The gRNA of the invention is capable of forming a complex with the DNA binding protein (Cas protein).
Carrier body
The invention also provides a vector comprising an adenosine deaminase, fusion protein, isolated nucleic acid molecule or polynucleotide as described above; preferably, it further comprises a regulatory element operably linked thereto.
In one embodiment, the regulatory element is selected from one or more of the following group: enhancers, transposons, promoters, terminators, leader sequences, polyadenylation sequences, and marker genes.
In one embodiment, the vector comprises a cloning vector, an expression vector, a shuttle vector, an integration vector.
In some embodiments, the vectors included in the system are viral vectors (e.g., retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated vectors, and herpes simplex vectors), but may also be of the plasmid, viral, cosmid, phage, etc. type, which are well known to those skilled in the art.
CRISPR system
The invention provides an engineered non-naturally occurring vector system, or a CRISPR-Cas system, comprising the fusion protein described above or a nucleic acid sequence encoding the fusion protein, wherein the DNA binding protein in the fusion protein is a Cas protein, and the gRNA is capable of binding to the Cas protein, and a nucleic acid encoding one or more of the guide RNAs described above.
In one embodiment, the nucleic acid sequence encoding the fusion protein and the nucleic acid encoding one or more guide RNAs are synthetic.
In one embodiment, the nucleic acid sequence encoding the fusion protein and the nucleic acid encoding one or more guide RNAs do not co-occur naturally.
The one or more guide RNAs target one or more target sequences in the cell. The one or more target sequences hybridize to a genomic locus of a DNA molecule encoding one or more gene products and the fusion protein is directed to the genomic locus of the DNA molecule of the one or more gene products, and the target sequence is modified, edited after the fusion protein reaches the target sequence position, whereby expression of the one or more gene products is altered or modified.
The cells of the invention include one or more of animals, plants or microorganisms.
In some embodiments, the fusion protein is codon optimized for expression in a cell.
The invention also provides an engineered non-naturally occurring carrier system that can include one or more carriers comprising:
a) A first regulatory element operably linked to the gRNA,
b) A second regulatory element operably linked to the fusion protein;
wherein components (a) and (b) are on the same or different supports of the system.
The first and second regulatory elements include promoters (e.g., constitutive promoters or inducible promoters), enhancers (e.g., 35S promoter or 35S enhanced promoter), internal Ribosome Entry Sites (IRES), and other expression control elements (e.g., transcriptional termination signals, such as polyadenylation signals and poly U sequences).
In some embodiments, the vectors in the system are viral vectors (e.g., retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated vectors, and herpes simplex vectors), but may also be of the plasmid, viral, cosmid, phage, etc. type, which are well known to those skilled in the art.
In some embodiments, the systems provided herein are in a delivery system. In some embodiments, the delivery system is a nanoparticle, liposome, exosome, microvesicle, or gene gun.
In one embodiment, the target sequence is a DNA or RNA sequence from a prokaryotic or eukaryotic cell. In one embodiment, the target sequence is a non-naturally occurring DNA or RNA sequence.
In one embodiment, the target sequence is present in a cell. In one embodiment, the target sequence is present in the nucleus or in the cytoplasm (e.g., organelle). In one embodiment, the cell is a eukaryotic cell. In other embodiments, the cell is a prokaryotic cell.
Protein-nucleic acid complexes/compositions
In another aspect, the invention provides a complex or composition comprising:
(i) A protein component selected from the group consisting of: the fusion protein, wherein the DNA binding protein in the fusion protein is Cas protein;
(ii) A nucleic acid component comprising (a) a guide sequence capable of hybridizing to a target sequence; and (b) a protein binding sequence capable of binding to a DNA binding protein in a fusion protein of the invention.
The protein component and the nucleic acid component are capable of binding to each other to form a complex.
In one embodiment, the nucleic acid component is a guide RNA in a CRISPR-Cas system.
In one embodiment, the complex or composition is non-naturally occurring or modified. In one embodiment, at least one component of the complex or composition is non-naturally occurring or modified. In one embodiment, the first component is non-naturally occurring or modified; and/or, the second component is non-naturally occurring or modified.
Delivery and delivery compositions
The fusion proteins, grnas, nucleic acid molecules, vectors, systems, complexes, and compositions of the invention may be delivered by any method known in the art. Such methods include, but are not limited to, electroporation, lipofection, nuclear transfection, microinjection, sonoporation, gene gun, calcium phosphate mediated transfection, cationic transfection, lipofection, dendritic transfection, heat shock transfection, nuclear transfection, magnetic transfection, lipofection, puncture transfection, optical transfection, reagent enhanced nucleic acid uptake, and delivery via liposomes, immunoliposomes, virosomes, artificial virosomes, and the like.
Accordingly, in another aspect, the present invention provides a delivery composition comprising a delivery vehicle, and one or more selected from any of the following: fusion proteins, grnas, nucleic acid molecules, vectors, systems, complexes, and compositions of the invention.
In one embodiment, the delivery vehicle is a particle.
In one embodiment, the delivery vehicle is selected from the group consisting of a lipid particle, a sugar particle, a metal particle, a protein particle, a liposome, an exosome, a microbubble, a gene gun, or a viral vector (e.g., replication defective retrovirus, lentivirus, adenovirus, or adeno-associated virus).
Host cells
The invention also relates to an in vitro, ex vivo or in vivo cell or cell line or their progeny comprising: fusion proteins, nucleic acid molecules, protein-nucleic acid complexes, vectors, delivery compositions of the invention are described.
In certain embodiments, the cell is a prokaryotic cell.
In certain embodiments, the cell is a eukaryotic cell. In certain embodiments, the cell is a mammalian cell. In certain embodiments, the cell is a human cell. In certain embodiments, the cell is a non-human mammalian cell, e.g., a non-human primate, bovine, ovine, porcine, canine, simian, rabbit, rodent (e.g., rat or mouse) cell. In certain embodiments, the cells are non-mammalian eukaryotic cells, such as cells of poultry birds (e.g., chickens), fish, or crustaceans (e.g., clams, shrimps). In certain embodiments, the cell is a plant cell, e.g., a cell of a monocot or dicot or a cell of a cultivated plant or a food crop such as tapioca, corn, sorghum, soybean, wheat, oat, or rice, e.g., an algae, tree, or production plant, fruit, or vegetable (e.g., a tree such as citrus, nut, eggplant, cotton, tobacco, tomato, grape, coffee, cocoa, etc.).
In certain embodiments, the cell is a stem cell or stem cell line.
In certain instances, a host cell of the invention comprises a modification of a gene or genome that is not present in its wild type.
Gene editing method and application
The fusion proteins, nucleic acids, the above-described compositions, the above-described CIRSPR/Cas systems, the above-described vector systems, the above-described delivery compositions, or the above-described host cells of the present invention may be used for any one or any of several of the following uses: targeting and/or editing a target nucleic acid; editing the double-stranded nucleic acid specifically; base editing double-stranded nucleic acid; base editing single stranded nucleic acids. In other embodiments, it may also be used to prepare reagents or kits for any one or any of several of the uses described above.
The invention also provides a method of editing a nucleic acid comprising the step of contacting a target region of a nucleic acid (e.g., a double stranded DNA sequence) with a complex comprising a fusion protein as described above and a gRNA; wherein the target region comprises a targeted base pair, and base substitution is performed on the targeted base pair in the target region. In one embodiment, the deaminase in the fusion protein is an adenosine deaminase and the targeted base pair is replaced by A: T to G: C.
T is the base paired by the component base pairs, and A and T are the base paired by the component base pairs; similarly, G.C refers to the bases that make up the base pair pairing as G and C.
The invention also provides the use of a fusion protein, a nucleic acid, the composition, the CIRSPR/Cas system, the vector system, the delivery composition or the host cell in gene editing; or in the preparation of a reagent or kit for gene editing.
In one embodiment, the gene editing is performed intracellularly and/or extracellularly.
In one embodiment, the gene editing is single base editing of the target gene.
The invention also provides a method of editing a target nucleic acid comprising contacting the target nucleic acid with the fusion protein, nucleic acid, composition, CIRSPR/Cas system, vector system, or delivery composition described above. In one embodiment, the method is editing the target nucleic acid either intra-or extracellular.
The gene editing or editing target nucleic acid includes the step of editing a single base of a target gene.
The editing may be performed in prokaryotic and/or eukaryotic cells.
In another aspect, the invention also provides a kit for gene editing comprising the above adenosine deaminase, fusion protein, gRNA, nucleic acid, the above composition, the above CIRSPR/Cas system, the above vector system, the above delivery composition, or the above host cell.
In another aspect, the invention provides the use of the above-described adenosine deaminase, fusion protein, nucleic acid, the above-described composition, the above-described CIRSPR/Cas system, the above-described vector system, the above-described delivery composition, or the above-described host cell in the preparation of a formulation or kit for:
(i) Gene or genome editing;
(ii) Editing a target sequence in a target locus to modify an organism;
(iii) Editing a single base;
(iv) Treatment of disease.
Preferably, the gene or genome editing is performed in or out of a cell.
Preferably, the treatment of the disease is treatment of a condition caused by a defect in the target sequence in the target locus.
Method for specifically modifying target nucleic acid
In another aspect, the invention also provides a method of specifically modifying a target nucleic acid, the method comprising: contacting a target nucleic acid with the fusion protein, nucleic acid, composition, CIRSPR/Cas system, vector system, or delivery composition.
The specific modification may occur in vivo or in vitro.
The specific modification may occur either intracellularly or extracellularly.
In some cases, the cell is selected from a prokaryotic cell or a eukaryotic cell, e.g., an animal cell, a plant cell, or a microbial cell.
Adenosine deaminase
As used herein, the term "adenosine deaminase" catalyzes the hydrolytic deamination of the nucleobase adenine. The adenosine deaminase provided herein (e.g., an engineered adenosine deaminase or an optimized adenosine deaminase) can convert adenosine (a) in DNA to an enzyme of inosine (I), such an adenosine deaminase can cause a: t to G: conversion of C base pairs. In some embodiments, the adenosine deaminase is a variant of a naturally occurring adenosine deaminase from an organism. In some embodiments, the adenosine deaminase is not present in nature. For example, in some embodiments, the adenosine deaminase has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identity with a naturally occurring adenosine deaminase.
DNA binding proteins
As used herein, the term "DNA-binding protein" or "DNA-binding protein domain" is any protein designated to locate at and bind to a particular target DNA nucleotide sequence (e.g., a genomic locus). The term includes RN a-programmable protein that binds (e.g., forms a complex) to one or more nucleic acid molecules (i.e., that include, for example, guide RNAs in the case of a Cas system) that direct or otherwise program the protein to locate a particular target nucleotide sequence (e.g., a DNA sequence) that is complementary to one or more nucleic acid molecules (or portions or regions thereof) to which the protein binds. Exemplary RNA programmable proteins are CR1SPR-Cas9 proteins, as well as Cas9 equivalents, homologs, orthologs, or paralogs, whether naturally occurring or non-naturally occurring (e.g., engineered or modified), and may include Cas9 equivalents from any type of CR1SPR system (e.g., type II, type V, type VI), including Cpfl (type V CRISPR-Cas system), C2cl (type V CRISPR-Cas system), C2 (type VI CRISPR-Cas system), C2C3 (type V CRISPR-Cas system), dCas9, geoCas9, cjCas9, cas12 a, cas12 b, casl2C, casl2d, casl2g, cassi2h, cas12i, dCas12i, and the like.
CRISPR system
As used herein, the term "regularly clustered, spaced short palindromic repeats (CRISPR) -CRISPR-associated (Cas) (CRISPR-Cas) system" or "CRISPR system" is used interchangeably and has the meaning commonly understood by those skilled in the art, which generally comprises transcripts or other elements related to the expression of a CRISPR-associated ("Cas") gene, or transcripts or other elements capable of directing the activity of the Cas gene. The Cas protein in the invention is Crispr associated protein.
CRISPR/Cas complexes
As used herein, the term "CRISPR/Cas complex" refers to a complex formed by directing RNA (guide RNA) or mature crRNA to bind to a Cas protein, comprising a direct repeat sequence that hybridizes to a target sequence and binds to a Cas protein, which complex is capable of recognizing and cleaving a polynucleotide that hybridizes to the guide RNA or mature crRNA.
Guide RNA (guide RNA, gRNA)
As used herein, the terms "guide RNA", "mature crRNA", "guide sequence" are used interchangeably and have the meaning commonly understood by those skilled in the art. In general, the guide RNA can comprise, consist essentially of, or consist of a direct repeat (direct repeat) and a guide sequence.
In certain instances, the guide sequence is any polynucleotide sequence that has sufficient complementarity to a target sequence to hybridize to the target sequence and direct specific binding of the CRISPR/Cas complex to the target sequence. In one embodiment, the degree of complementarity between a guide sequence and its corresponding target sequence is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99% when optimally aligned. It is within the ability of one of ordinary skill in the art to determine the optimal alignment. For example, there are published and commercially available alignment algorithms and programs such as, but not limited to, the Smith-Waterman algorithm (Smith-Waterman), bowtie, geneious, biopython, and SeqMan in ClustalW, matlab.
Target sequence
"target sequence" refers to a polynucleotide targeted by a guide sequence in a gRNA, e.g., a sequence that has complementarity to the guide sequence, wherein hybridization between the target sequence and the guide sequence will promote the formation of a CRISPR/Cas complex (including Cas proteins and grnas). Complete complementarity is not necessary so long as sufficient complementarity exists to cause hybridization and promote the formation of a CRISPR/Cas complex.
The target sequence may comprise any polynucleotide, such as DNA or RNA. In some cases, the target sequence is located either inside or outside the cell. In some cases, the target sequence is located in the nucleus or cytoplasm of the cell. In some cases, the target sequence may be located within an organelle of a eukaryotic cell, such as a mitochondria or chloroplast. Sequences or templates that can be used for recombination into a target locus comprising the target sequence are referred to as "editing templates" or "editing polynucleotides" or "editing sequences". In one embodiment, the editing template is an exogenous nucleic acid. In one embodiment, the recombination is homologous recombination.
In the present invention, a "target sequence" or "target polynucleotide" or "target nucleic acid" may be any polynucleotide that is endogenous or exogenous to a cell (e.g., a eukaryotic cell). For example, the target polynucleotide may be a polynucleotide that is present in the nucleus of a eukaryotic cell. The target polynucleotide may be a sequence encoding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or unwanted DNA). In some cases, the target sequence should be related to the Protospacer Adjacent Motif (PAM).
Base editing
The term "base editing" refers to a genomic editing technique that involves converting a particular nucleic acid base into another base at a targeted genomic locus. In certain embodiments, this may be accomplished without the need for double-stranded DNA breaks (DSBs) or single-stranded breaks (nicking). To date, other genome editing techniques including CRISPR-based systems begin with the introduction of DSBs at loci of interest. Subsequently, cellular DNA repair enzymes repair breaks, often resulting in random insertions or deletions (indels) of bases at the DSB site. However, when it is desired to introduce or correct point mutations at the target locus instead of random disruption of the entire gene, these genome editing techniques are unsuitable because of the low correction rate (typically 0.1% to 5%), where the predominant genome editing product is indel. To increase the efficiency of gene correction without introducing Rando indels, the inventors used adenosine deaminase in combination with the CRISPR system to convert one DNA base directly to another without forming DSBs.
Wild type
As used herein, the term "wild-type" has the meaning commonly understood by those skilled in the art, which refers to a typical form of an organism, strain, gene, or a characteristic that, when it exists in nature, differs from a mutant or variant form, which may be isolated from a source in nature and not intentionally modified by man.
Non-naturally occurring
As used herein, the terms "non-naturally occurring" or "engineered" are used interchangeably and refer to human involvement. When these terms are used to describe a nucleic acid molecule or polypeptide, it means that the nucleic acid molecule or polypeptide is at least substantially free from at least one other component to which it is associated in nature or as found in nature.
Identity of
As used herein, the term "identity" is used to refer to the match of sequences between two polypeptides or between two nucleic acids. When a position in both sequences being compared is occupied by the same base or amino acid monomer subunit (e.g., a position in each of two DNA molecules is occupied by adenine, or a position in each of two polypeptides is occupied by lysine), then the molecules are identical at that position. The "percent identity" between two sequences is a function of the number of matched positions shared by the two sequences divided by the number of positions to be compared x 100. For example, if 6 out of 10 positions of two sequences match, then the two sequences have 60% identity. For example, the DNA sequences CTGACT and CAGGTT share 50% identity (3 out of 6 positions in total are matched). Typically, the comparison is made when two sequences are aligned to produce maximum identity. Such alignment may be conveniently performed using, for example, a computer program such as the Align program (DNAstar, inc.) Needleman et al (1970) j.mol.biol.48: 443-453. The percent identity between two amino acid sequences can also be determined using the algorithms of E.Meyers and W.Miller (Comput. Appl biosci.,4:11-17 (1988)) which have been integrated into the ALIGN program (version 2.0), using the PAM120 weight residue table (weight residue table), the gap length penalty of 12 and the gap penalty of 4. Furthermore, percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J MoI biol.48:444-453 (1970)) algorithm that has been incorporated into the GAP program of the GCG software package (available on www.gcg.com), using the Blossum 62 matrix or PAM250 matrix, and GAP weights (GAP weights) of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6.
Carrier body
The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid molecule linked thereto. Vectors include, but are not limited to, single-stranded, double-stranded, or partially double-stranded nucleic acid molecules; a nucleic acid molecule comprising one or more free ends, free ends (e.g., circular); a nucleic acid molecule comprising DNA, RNA, or both; and other diverse polynucleotides known in the art. The vector may be introduced into a host cell by transformation, transduction or transfection such that the genetic material elements carried thereby are expressed in the host cell. A vector may be introduced into a host cell to thereby produce a transcript, protein, or peptide, including from a protein, fusion protein, isolated nucleic acid molecule, or the like (e.g., a CRISPR transcript, such as a nucleic acid transcript, protein, or enzyme) as described herein. A vector may contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. In addition, the vector may also contain a replication origin.
One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA fragments may be inserted, for example, by standard molecular cloning techniques.
Another type of vector is a viral vector in which a virus-derived DNA or RNA sequence is present in a vector used to package a virus (e.g., retrovirus, replication-defective retrovirus, adenovirus, replication-defective adenovirus, and adeno-associated virus). Viral vectors also comprise polynucleotides carried by a virus for transfection into a host cell. Certain vectors (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors) are capable of autonomous replication in a host cell into which they are introduced.
Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operably linked. Such vectors are referred to herein as "expression vectors".
Host cells
As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including, but not limited to, prokaryotic cells such as e.g. escherichia coli or bacillus subtilis, eukaryotic cells such as microbial cells, fungal cells, animal cells and plant cells.
Those skilled in the art will appreciate that the design of the expression vector may depend on factors such as the choice of host cell to be transformed, the desired level of expression, and the like.
Regulatory element
As used herein, the term "regulatory element" is intended to include promoters, enhancers, internal Ribosome Entry Sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly U sequences), the detailed description of which may be found in goldel (Goeddel), gene expression techniques: methods of enzymology (GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY) 185, academic Press (Academic Press), san Diego (San Diego), calif. (1990). In some cases, regulatory elements include those sequences that direct constitutive expression of a nucleotide sequence in many types of host cells as well as those sequences that direct expression of the nucleotide sequence in only certain host cells (e.g., tissue-specific regulatory sequences). Tissue-specific promoters may primarily direct expression in a desired tissue of interest, such as muscle, neurons, bone, skin, blood, specific organs (e.g., liver, pancreas), or specific cell types (e.g., lymphocytes). In some cases, regulatory elements may also direct expression in a time-dependent manner (e.g., in a cell cycle-dependent or developmental stage-dependent manner), which may or may not be tissue or cell type specific. In certain instances, the term "regulatory element" encompasses enhancer elements, such as WPRE; a CMV enhancer; the R-U5' fragment in the LTR of HTLV-I (mol. Cell. Biol., volume 8 (1), pages 466-472, 1988), the SV40 enhancer, and the intron sequence between exons 2 and 3 of rabbit beta-globin (Proc. Natl. Acad. Sci. USA., volume 78 (3), pages 1527-31, 1981).
Promoters
As used herein, the term "promoter" has a meaning well known to those skilled in the art and refers to a non-coding nucleotide sequence located upstream of a gene that is capable of initiating expression of a downstream gene. Constitutive (constitutive) promoters are nucleotide sequences of: when operably linked to a polynucleotide encoding or defining a gene product, it results in the production of the gene product in the cell under most or all physiological conditions of the cell. An inducible promoter is a nucleotide sequence which, when operably linked to a polynucleotide encoding or defining a gene product, results in the production of the gene product in a cell, essentially only when an inducer corresponding to the promoter is present in the cell. Tissue specific promoters are nucleotide sequences that: when operably linked to a polynucleotide encoding or defining a gene product, it results in the production of the gene product in the cell substantially only if the cell is a cell of the tissue type to which the promoter corresponds.
NLS
A "nuclear localization signal" or "nuclear localization sequence" (NLS) is an amino acid sequence that "tags" a protein for introduction into the nucleus by nuclear transport, i.e., a protein with NLS is transported to the nucleus. Typically, NLS contains positively charged Lys or Arg residues exposed at the protein surface. Exemplary nuclear localization sequences include, but are not limited to, NLS from: SV40 large T antigen, EGL-13, c-Myc, and TUS proteins. In some embodiments, the NLS comprises PKKKRKV sequence. In some embodiments, the NLS comprises the AVKRPAATKKAGQAKKKKLD sequence. In some embodiments, the NLS comprises the PAAKRVKLD sequence. In some embodiments, the NLS comprises the MSRRRKANPTKLSENAKKLAKEVEN sequence. In some embodiments, the NLS comprises the KLKIKRPVK sequence. Other nuclear localization sequences include, but are not limited to, the acidic M9 domain of hnRNP A1, the sequences KIPIK and PY-NLS in yeast transcription repressor Mat. Alpha.2.
Operatively connected to
As used herein, the term "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the one or more regulatory elements in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
Complementarity and method of detecting complementary
As used herein, the term "complementarity" refers to the ability of a nucleic acid to form one or more hydrogen bonds with another nucleic acid sequence by means of a conventional watson-crick or other non-conventional type. Percent complementarity means the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (e.g., watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 of 10 are 50%, 60%, 70%, 80%, 90%, and 100% complementary). "fully complementary" means that all consecutive residues of one nucleic acid sequence form hydrogen bonds with the same number of consecutive residues in one second nucleic acid sequence. "substantially complementary" as used herein refers to a degree of complementarity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more nucleotides, or to two nucleic acids that hybridize under stringent conditions.
Stringent conditions
As used herein, "stringent conditions" for hybridization refers to conditions under which a nucleic acid having complementarity to a target sequence hybridizes predominantly to the target sequence and does not substantially hybridize to non-target sequences. Stringent conditions are typically sequence-dependent and will vary depending on a number of factors. In general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence.
Hybridization
The term "hybridization" or "complementary" or "substantially complementary" means that a nucleic acid (e.g., RNA, DNA) comprises a nucleotide sequence that enables it to bind non-covalently, i.e., form base pairs and/or G/U base pairs with another nucleic acid in a sequence-specific, antiparallel manner (i.e., the nucleic acid specifically binds to the complementary nucleic acid), "anneal" or "hybridize".
Hybridization requires that the two nucleic acids contain complementary sequences, although there may be mismatches between bases. Suitable conditions for hybridization between two nucleic acids depend on the length of the nucleic acids and the degree of complementarity, variables well known in the art. Typically, the hybridizable nucleic acid is 8 nucleotides or more in length (e.g., 10 nucleotides or more, 12 nucleotides or more, 15 nucleotides or more, 20 nucleotides or more, 22 nucleotides or more, 25 nucleotides or more, or 30 nucleotides or more).
It will be appreciated that the sequence of a polynucleotide need not be 100% complementary to the sequence of its target nucleic acid to specifically hybridize. Polynucleotides may comprise 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, 99% or more, 99.5% or more, or 100% sequence complementarity to a target region in a target nucleic acid sequence to which it hybridizes.
Hybridization of the target sequence to the gRNA represents that at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the target sequence and the nucleic acid sequence of the gRNA can hybridize to form a complex; or at least 12, 15, 16, 17, 18, 19, 20, 21, 22 or more bases of the nucleic acid sequence representing the target sequence and the gRNA may be complementarily paired and hybridized to form a complex.
Expression of
As used herein, the term "expression" refers to a process whereby a polynucleotide is transcribed from a DNA template (e.g., into mRNA or other RNA transcript) and/or a process whereby the transcribed mRNA is subsequently translated into a peptide, polypeptide, or protein. Transcripts and encoded polypeptides may be collectively referred to as "gene products". If the polynucleotide is derived from genomic DNA, expression may include splicing of mRNA in eukaryotic cells.
Joint
As used herein, the term "linker" refers to a linear polypeptide formed from multiple amino acid residues joined by peptide bonds. The linker of the invention may be an amino acid sequence that is synthesized artificially, or a naturally occurring polypeptide sequence, such as a polypeptide having the function of a hinge region. Such linker polypeptides are well known in the art (see, e.g., holliger, P. Et al (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; poljak, R.J. Et al (1994) Structure 2:1121-1123).
Treatment of
As used herein, the term "treating" refers to treating or curing a disorder, delaying the onset of symptoms of a disorder, and/or delaying the progression of a disorder.
A subject
As used herein, the term "subject" includes, but is not limited to, various animals, plants, and microorganisms.
Animals
Such as mammals, e.g., bovine, equine, ovine, porcine, canine, feline, lagomorph (e.g., mice or rats), non-human primate (e.g., macaque or cynomolgus) or human. In certain embodiments, the subject (e.g., human) has a disorder (e.g., a disorder resulting from a disease-related gene defect).
Plants and methods of making the same
The term "plant" is understood to mean any differentiated multicellular organism capable of photosynthesis, including crop plants at any stage of maturity or development, in particular monocotyledonous or dicotyledonous plants, vegetable crops, including artichoke, broccoli, sesame seed, leek, asparagus, lettuce (e.g., head lettuce, leaf lettuce), cabbage (bok choy), yellow arrowroot, melons (e.g., melon, watermelon, columbian melon (crenhaw), white melon, cantaloupe), rape crops (e.g., cabbage, broccoli, chinese cabbage, kohlrabi, chinese cabbage), artichoke, carrot, cabbage (napa), okra, onion, celery, parsley, chick pea, parsnip, chicory, pepper, potato, cucurbit (e.g., zucchini, cucumber, zucchini, melon, pumpkin), radish, dried onion, turnip cabbage, purple eggplant (also known as eggplant), salon, chicory, shallot, chicory, garlic, spinach, green onion, melon, green leafy vegetables (greens), beet (sugar beet and fodder beet), sweet potato, lettuce, horseradish, tomato, turnip, spice; fruit and/or vining crops, such as apples, apricots, cherries, nectarines, peaches, pears, plums, prunes, cherries, quince, almonds, chestnuts, hazelnuts, pecans, pistachios, walnuts, oranges, blueberries, boysenberries (boysenberries), redberries, currants, rowfruits, raspberries, strawberries, blackberries, grapes, avocados, bananas, kiwi fruits, persimmons, pomegranates, pineapple, tropical fruits, pome fruits, melons, mangoes, papaya, and litchis; field crops, such as clover, alfalfa, evening primrose, white mango, corn/maize (forage maize, sweet maize, popcorn), hops, jojoba, peanuts, rice, safflower, small grain cereal crops (barley, oat, rye, wheat, etc.), sorghum, tobacco, kapok, legumes (beans, lentils, peas, soybeans), oleaginous plants (rape, mustard, olives, sunflower, coconut, castor oil plants, cocoa beans, groundnut), arabidopsis, fibrous plants (cotton, flax, jute), camphorridae (cinnamon, camphordons), or a plant such as coffee, sugarcane, tea, and natural rubber plants; and/or flower bed plants, such as flowering plants, cactus, fleshy plants and/or ornamental plants, and trees, such as forests (broadleaf and evergreen trees, e.g., conifers), fruit trees, ornamental trees, and nut-bearing trees, and shrubs and other seedlings.
Advantageous effects of the application
The application can be used for single base editing of target nucleic acid by improving the adenosine deaminase and fusing the adenosine deaminase with DNA binding protein, improves the single base editing efficiency and has wide application prospect.
Embodiments of the present application will be described in detail below with reference to the accompanying drawings and examples, but it will be understood by those skilled in the art that the following drawings and examples are only for illustrating the present application and are not to be construed as limiting the scope of the present application. Various objects and advantageous aspects of the present application will become apparent to those skilled in the art from the following detailed description of the preferred embodiments and the accompanying drawings.
The sequence information related to the application is as follows:
/>
/>
/>
/>
drawings
FIG. 1 is a schematic diagram of an ABE editing tool.
FIG. 2 is a schematic diagram of the operation of the ABE fluorescence reporting system.
FIG. 3 shows the results of single base editing efficiency of ABE vector composed of adenosine deaminase and dCAS12i 3; wherein WT is a wild type ABE9 editing vector, and I95R is an ABE editing vector formed by mutating TadA9 at the 95 th amino acid site.
FIG. 4 shows the single base editing efficiency results of adenosine deaminase with different dCAs12i 3; WT is a wild-type ABE9 editing vector, which consists of wild-type dCAS12I3 and wild-type TadA9, T235R-E328R is a single-base editor formed by dCAS12I3 based on 235 th and 328 th amino acid mutation and wild-type TadA9, and I95R-T235RE328R is a single-base editor formed by dCAS12I3 based on 235 th and 328 th amino acid mutation and 95 th amino acid site mutation TadA 9.
FIG. 5 verification of the editing activity of ABE vector consisting of single site saturation mutated adenosine deaminase and dCAS12i 3.
Detailed Description
The following examples are only intended to illustrate the invention and are not intended to limit it. The experiments and methods described in the examples were performed substantially in accordance with conventional methods well known in the art and described in various references unless specifically indicated. For example, for the conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA used in the present invention, reference may be made to Sambrook (Sambrook), friech (Fritsch) and manitis (Maniatis), molecular cloning: laboratory Manual (MOLECULAR CLONING: A LABORATORY MANUAL), edit 2 (1989); the handbook of contemporary molecular biology (CURRENT PROTOCOLS IN MOLECULAR BIOLOGY) (edited by f.m. ausubel (f.m. ausubel) et al, (1987)); series (academic publishing company) of methods in enzymology (METHODS IN ENZYMOLOGY): PCR 2: practical methods (PCR 2:A PRACTICAL APPROACH) (m.j. Maxfresen (m.j. Macpherson), b.d. black ms (b.d. hames) and g.r. taylor (1995)), harlow and Lane (Lane) edits (1988), antibodies: laboratory Manual (ANTIBODIES, A LABORATORY MANUAL), animal cell CULTURE (ANIMAL CELL CULTURE) (R.I. French Lei Xieni (R.I. Freshney) eds. (1987)).
In addition, the specific conditions are not specified in the examples, and the process is carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention. Those skilled in the art will appreciate that the examples describe the invention by way of example and are not intended to limit the scope of the invention as claimed. All publications and other references mentioned herein are incorporated by reference in their entirety.
EXAMPLE 1 screening of mutant adenosine deaminase
Predicting the structure of TadA9 (the amino acid sequence is shown as SEQ ID No. 1), and the applicant predicts key amino acid sites of TadA9 which possibly influence the biological function of the TadA9 through bioinformatics, selects related sites to establish a mutant library and screens the mutant library by using a fluorescence reporting system. In this embodiment, the 95 th I from the N-terminus of SEQ ID No.1 is mutated to R to give a mutated adenosine deaminase TadA9-I95R.
The fluorescence reporting system of this embodiment refers to experimental methods well known to those skilled in the art, mutating wild-type Cas12i3 (cas12f.4 in CN111757889B, in this example referred to as Cas12i 3) to obtain dCas12i3 (amino acid sequence shown as SEQ ID No. 2) with inactivated nuclease activity, ligating the mutant library with dCas12i3 to form a CMV-ABE9 mutant-dCas 12i3 expression loop into pcdna3.3 expression vector. Target gBFP is designed, and is connected with DR sequence of Cas12i3 together to form U6-DR-gBFP expression loop which is connected into pcDNA3.3 expression vector, and crRNA sequence is AGAGAAUGUGUGCAUAGUCACAC GTGTGTTCTGCTAGTAGTGGThe underlined region is the targeting region; the pcDNA3.3 expression vector also contains a mutated BFP fluorescent protein, as shown in figure 2, CTG in BFP is mutated into a stop codon CTA, translation is terminated in advance, BFP fluorescence is not detected, A is changed into G if ABE has a function, the stop codon is destroyed, translation is not terminated in advance, and BFP fluorescence can be detected; the constructed expression vector is transfected into a 293T cell line, and BFP ratio is detected and calculated through fluorescence of a flow cytometer after 48 hours; single base editing efficiency was calculated as BFP positive cell number/total cell number.
A schematic of the editing elements for constructing ABE using TadA9 is shown in FIG. 1, where dBP is the tag designed for screening adenosine deaminase mutant positive cells.
As shown in FIG. 1, the adenosine deaminase is N-terminal to dCAS12i3, linked by an XTEN linker; the other ends of deaminase and dCas12i3 are also ligated with NLS. The above are merely exemplary ways to attach adenosine deaminase and dCas12i3, and in other embodiments, the positions or order of attachment of the above elements may be adjusted by one skilled in the art.
As a result, as shown in FIG. 3, according to the result of screening by the fluorescence reporting system, the single base editing efficiency of the ABE vector (I95R in FIG. 3) composed of the mutant TadA9, tadA9-I95R (the 95 th amino acid was mutated to R as compared with SEQ ID No. 1) and the wild type dCAS12I3 (shown in SEQ ID No. 2) was 2 times as high as that of the wild type ABE vector (the wild type TadA9 and the wild type dCAS12I3, WT in FIG. 3). The above results reflect that the mutation of the 95 th amino acid site of TadA9 improves the single base editing efficiency.
In order to obtain an ABE system with higher single base editing efficiency, the applicant further optimizes the Cas protein, specifically, on the basis of dCAS12i3, the 235 th and 328 th amino acid sites are mutated to obtain a T235R-E328R protein (compared with SEQ ID No.2, the 235 th amino acid is mutated into R, and the 328 th amino acid is mutated into R).
In the same manner as described above, the single base editing efficiency of the T235R-E328R protein was further verified when used with wild-type adenosine deaminase TadA9 or mutant adenosine deaminase TadA 9-I95R; as a result, as shown in FIG. 4, the single base editing efficiency of T235R-E328R (ABE vector composed of T235R-E328R and wild-type tadA9, FIG. 4) was 4 times that of WT (ABE vector composed of wild-type dCAs12i3 and wild-type tadA9, FIG. 4); the single base editing efficiency of I95R-T235RE328R (ABE vector composed of T235R-E328R and TadA9-I95R, FIG. 4, I95R-T235R E R) was 7 times that of wild-type WT (ABE vector composed of dCAs12I3 and wild-type TadA9, FIG. 4, WT) and 1.75 times that of T235R-E328R (ABE vector composed of T235R-E328R and wild-type TadA9, FIG. 4).
The above results show that the mutant adenosine deaminase TadA9-I95R can construct single base editing tools with different DNA binding proteins, and greatly improves the efficiency of single base editing.
Example 2 verification of the Activity of Single Point saturation mutated adenosine deaminase
A variant of TadA9 was generated by PCR-based site-directed mutagenesis, and SEQ ID No.1 was subjected to saturation mutagenesis at position 95 from the N-terminus to mutate it into A, N, D, C, Q, E, G, H, S, L, K, M, F, P, T, W, Y, V, respectively.
The specific method is that the DNA sequence design of the TadA9 protein is divided into two parts by taking a mutation site as a center, primers are designed aiming at the mutation site, each two pairs of primers correspond to one amino acid mutation, the two pairs of primers are designed to amplify the two parts of DNA sequences respectively, simultaneously, the sequences needing mutation are introduced into the primers, and finally, the two fragments are loaded on a pcDNA3.3-eGFP carrier in a Gibson cloning mode. The combination of mutants was constructed by splitting the TadA9 protein DNA into fragments and using PCR, gibson clone. Fragment amplification kit: transStart FastPfu DNAPolymerase (containing 2.5mM dNTPs) and the specific experimental procedures are shown in the specification. Glue recovery kit:gel DNAExtraction Mini Kit, the detailed experimental procedures are shown in the specification. Kit for vector construction: pEASY-Basic Seamless Cloning and Assembly Kit (CU 201-03), the specific experimental procedures are described in the specification.
Based on the above amino acid mutation sites, a wild-type protein (WT) of TadA9, and a protein (named mutation type) in which saturation mutation occurs at a single site of amino acid at position 95 were obtained, respectively: I95A, I95N, I95D, I95 5497 95Q, I95E, I95G, I95H, I95S, I95 3995K, I95M, I95F, I95P, I T, I95 3995Y, I V.
The BFP fluorescence reporting system in example 1 was used to construct a fluorescence reporting system suitable for ABE validation by ligating the TadA9 mutant with wild dCAs12i3 (amino acid sequence shown in SEQ ID No. 2) respectively. As shown in FIG. 5, WT is an ABE single base editor composed of wild-type dCAs12I3 and wild-type TadA9, I95A is an ABE single base editor composed of wild-type dCAs12I3 and TadA9 mutated at position A, I95N is an ABE single base editor composed of wild-type dCAs12I3 and TadA9 mutated at position N, I95D is an ABE single base editor composed of wild-type dCAs12I3 and TadA9 mutated at position D, I95C is an ABE single base editor composed of wild-type dCAs12I3 and TadA9 mutated at position 95C, I95Q is an ABE single base editor composed of wild-type dCAs12I3 and TadA9 mutated at position 95Q, I95E is an ABE single base editor composed of wild-type dCAs12I3 and TadA9 mutated at position 95, I95G is an ABE single base editor composed of wild-type dCAs12I3 and TadA9 mutated at position 95, an ABE single base editor composed of I95S with wild type dCAS12I3 and TadA9 with S mutation at position 95, an ABE single base editor composed of I95L with wild type dCAS12I3 and TadA9 with L mutation at position 95, an ABE single base editor composed of I95K with wild type dCAS12I3 and TadA9 with K mutation at position 95, an ABE single base editor composed of I95M with wild type dCAS12I3 and TadA9 with M mutation at position 95, an ABE single base editor composed of I95F with wild type dCAS12I3 and TadA9 with F mutation at position 95, an ABE single base editor composed of I95P with wild type dCAS12I3 and TadA9 with P mutation at position 95, an ABE single base editor composed of I95T with wild type dCAS12I3 and TadA9 with T mutation at position 95, an ABE single base editor composed of I95W 12I3 with Y mutation at position 95 with ABE 9 with F mutation at position 95, I95V is an ABE single base editor composed of wild dCAs12I3 and TadA9 mutated to V at position 95. According to the screening results of the fluorescence reporting system of FIG. 5, the activity of the ABE single base editor composed of I95A, I95N, I F and dCAS12I3 is obviously enhanced compared with that of the wild type ABE single base editor.
The above results indicate that when the 95 th amino acid site of TadA9 is mutated to A, N, F or R, the single base editing efficiency can be improved.
Although specific embodiments of the invention have been described in detail, those skilled in the art will appreciate that: many modifications and variations of details may be made to adapt to a particular situation and the invention is intended to be within the scope of the invention. The full scope of the invention is given by the appended claims together with any equivalents thereof.
Claims (18)
1. A mutant adenosine deaminase having a mutation at an amino acid position corresponding to position 95 in the amino acid sequence shown in SEQ ID No.1, compared to the amino acid sequence of the parent adenosine deaminase; preferably, the amino acid at position 95 is mutated to A, N, F or R.
2. The mutant adenosine deaminase of claim 1, wherein the amino acid sequence of the parent adenosine deaminase has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity compared to SEQ ID No. 1; preferably, the parent adenosine deaminase is derived from e.
3. A fusion protein comprising a DNA binding protein and an adenosine deaminase according to any of claims 1-2.
4. The fusion protein of claim 3, wherein the DNA-binding protein is a Cas protein; preferably, the Cas protein is selected from the group consisting of Cas9, cas9n, dCas9, casX, casY, C cl, C2, C2C3, geoCas9, cjCas9, casl2a, casl2b, casl2g, casl2h, casl2i, cas12j, casl3b, casl3C, casl3d, casl4, csn2, xCas9, cas9-NG, lbCasl2a, enaascas 2a, cas9-KKH, cyclic substitution Cas9, argonaute (Ago) domains, smacas 9, spy-macCas9, spaCas 9-NRRH, spaCas9-NRTH, spaCas9-NRCH, cas9-NG-CP1041, cas 9-NG-qr, dCas12i, n 12i, and variants thereof, preferably, the Cas protein is Cas12i.
5. The fusion protein of claim 3, wherein the DNA binding protein is a nuclease-inactivated Cas protein.
6. The fusion protein of any one of claims 3-5, wherein the DNA binding protein and the adenosine deaminase are linked by a linker.
7. The fusion protein of any one of claims 3-5, further comprising a Nuclear Localization Sequence (NLS).
8. An isolated polynucleotide encoding the adenosine deaminase of any of claims 1-2, or encoding the fusion protein of claims 3-7.
9. A vector comprising the polynucleotide of claim 8 operably linked to regulatory elements.
10. A CRISPR-Cas system, comprising the fusion protein of any one of claims 3-7 and at least one gRNA; the DNA binding protein in the fusion protein is a Cas protein, and the gRNA is capable of binding to the Cas protein.
11. A composition, characterized in that it comprises:
(i) A protein component selected from the group consisting of: the fusion protein of any one of claims 3-7, wherein the DNA-binding protein in the fusion protein is a Cas protein;
(ii) A nucleic acid component that is a gRNA capable of binding to the Cas protein.
12. An engineered host cell comprising the adenosine deaminase of any of claims 1-2, or the fusion protein of any of claims 3-7, or the polynucleotide of claim 8, or the vector of claim 9, or the CRISPR-Cas system of claim 10, or the composition of claim 11.
13. Use of the adenosine deaminase of any of claims 1-2, or the fusion protein of any of claims 3-7, or the polynucleotide of claim 8, or the vector of claim 9, or the CRISPR-Cas system of claim 10, or the composition of claim 11, or the host cell of claim 12 in gene editing; or in the preparation of a reagent or kit for gene editing.
14. The use of claim 13, wherein the gene editing is single base editing of the target gene.
15. A kit for gene editing comprising the adenosine deaminase of any of claims 1-2, or the fusion protein of any of claims 3-7, or the polynucleotide of claim 8, or the vector of claim 9, or the CRISPR-Cas system of claim 10, or the composition of claim 11, or the host cell of claim 12.
16. Use of the adenosine deaminase of any of claims 1-2, or the fusion protein of any of claims 3-7, or the polynucleotide of claim 8, or the vector of claim 9, or the CRISPR-Cas system of claim 10, or the composition of claim 11, or the host cell of claim 12, in the preparation of a formulation or kit for: editing the target sequence in the target locus to modify the organism, or treatment of the disease.
17. A method of editing a nucleic acid, wherein the method is a method for non-disease diagnosis and treatment purposes, comprising the step of contacting a target region of a nucleic acid with the fusion protein of any one of claims 3-7 and a gRNA comprising a segment capable of binding to a Cas protein in the fusion protein of any one of claims 3-7 and capable of binding to the target region of the nucleic acid; wherein the target region comprises a targeted base pair, the fusion protein being capable of base substitution of the targeted base pair.
18. The method of claim 17, wherein the targeted base pair is replaced by a: T to G: C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2023102574531 | 2023-03-13 | ||
CN202310257453 | 2023-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116732012A true CN116732012A (en) | 2023-09-12 |
Family
ID=87910515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310517357.6A Pending CN116732012A (en) | 2023-03-13 | 2023-05-06 | Base editor and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116732012A (en) |
-
2023
- 2023-05-06 CN CN202310517357.6A patent/CN116732012A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114672473B (en) | Optimized Cas protein and application thereof | |
CN116334037A (en) | Novel Cas enzymes and systems and uses | |
CN114410609B (en) | Cas protein with improved activity and application thereof | |
CN114438055B (en) | Novel CRISPR enzymes and systems and uses | |
CN112105728A (en) | CRISPR/Cas effector proteins and systems | |
WO2022166895A1 (en) | Crispr enzyme and system and use thereof | |
WO2023202116A1 (en) | Cas enzyme, system and use | |
CN116004573B (en) | Cas protein with improved editing activity and application thereof | |
CN117106752A (en) | Optimized Cas12 proteins and uses thereof | |
CN116286739A (en) | Mutant Cas proteins and uses thereof | |
JP2017500888A (en) | Nucleotide sequence encoding WESCHEL-related homeobox 4 (WOX4) protein from P. thaliana and juvenile and methods of use | |
CN114277015B (en) | CRISPR enzyme and application | |
CN116732012A (en) | Base editor and application thereof | |
CN117821424B (en) | Optimized IscB protein and application thereof | |
CN118086263A (en) | Optimized base editing tool and application thereof | |
CN116790559B (en) | HNH domain-fused V-type Cas enzyme and application thereof | |
CN117327679A (en) | Base editing tool and application thereof | |
WO2024040874A1 (en) | Mutated cas12j protein and use thereof | |
CN117821424A (en) | Optimized IscB protein and application thereof | |
WO2023173682A1 (en) | Optimized cas protein and use thereof | |
WO2023231456A1 (en) | Optimized cas protein and use thereof | |
WO2023174249A1 (en) | Cas protein having improved activity and use thereof | |
WO2023143150A1 (en) | Novel cas enzyme and system and use | |
CN116555225A (en) | Cas proteins with improved activity and uses thereof | |
CN117286123A (en) | Optimized Cas protein and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |